AVP and metabolic syndrome: Previous studies have demonstrated that plasma copeptin (PCop) is positively and independently associated with incident type 2 diabetes mellitus [1–3], metabolic syndrome [4, 5], progression of chronic kidney disease [6–9], and cardiovascular disease [10–12].